Acorda Therapeutics, Inc. (Nasdaq: ACOR) is set to regain global commercialization rights to FAMPYRA® (fampridine) as Biogen terminates the license and collaboration agreement, effective January 1, 2025. FAMPYRA is used for improving walking in adults with multiple sclerosis (MS) in the European Union and other territories. Acorda will take over commercialization outside the United States during 2024, ensuring continued access to the medication worldwide. The transition is part of the collaborative efforts between Acorda and Biogen.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FAMPYRA is indicated in the European Union and other territories throughout the world for the improvement of walking in adults with multiple sclerosis (MS) with walking disability. Acorda markets the medication as AMPYRA® (dalfampridine) in the United States.
Acorda and Biogen are working together toward a transition for Acorda to commercialize and supply FAMPYRA for the great majority of people with MS outside the United States currently being served. Acorda plans to assume commercialization responsibilities as soon as possible during 2024 as marketing authorization transfers and distribution arrangements are finalized for each territory.
“We are excited to bring FAMPYRA in-house, which we believe will add significant value to Acorda, and allow us to continue to provide access to this important medication for people with MS around the world,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. “We are grateful to Biogen for their partnership over the last 14 years, and for their commitment to collaborating with us during this transition.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Bio Space
